EVENTS · SEPN
PEERS
EARNINGS
Septerna shares rose after the company announced it selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease, backed by new preclinical data presented at a medical meeting
| Series | 1W | 1M |
|---|---|---|
| SEPN | +8.2% | +34.2% |
| Peers | +1.8% | +5.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 73 | 98 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q2 FY2026 | −0.43 | −0.29 | +33.26% | +23.00% |
| Q1 FY2026 | −0.43 | −0.19 | +55.29% | +4.06% |
| Q4 FY2025 | −0.26 | −0.24 | +7.26% | −2.64% |
| Q3 FY2025 | 0.81 | −0.09 | −111.11% | +3.94% |
| Series | 1W | 1M |
|---|---|---|
| SEPN | +8.2% | +34.2% |
| Peers | +1.8% | +5.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 73 | 98 |
